Daniela Dottore Stagna

Ms. Daniela Dottore Stagna

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
FUFabiana Uomo
Fabiana Uomo
CFChiara De Falco
Chiara De Falco
FBFerdinando Barretta
Ferdinando Barretta
NMNancy Messina
Nancy Messina
RSRosa Redenta De Simone
Rosa Redenta De Simone
Cristina MazzaccaraCristina Mazzaccara
Cristina Mazzaccara
Background/Objectives: Mitochondrial diseases (MDs) are heterogeneous genetic disorders caused by oxidative phosphorylation impairment, governed by both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). Traditional multi-step diagnostic strategies, involving mtDNA long-range PCR and screening of a limited set of nuclear genes, often leave many patients without a molecular diagnosis. This study evaluates the clinical implementation of a single-step MITO-NUCLEAR Next-Generation (NGS) panel (whole mtDNA and 254 nuclear genes), previously developed and validated by our group. Methods: Buccal swab DNA from 70 patients with suspected MDs was sequenced using an optimized probe dilution ratio (1:500, mtDNA: nDNA), achieving mean depths of ~10,000× (mtDNA) and 110× (nDNA). Variants were classified according to ACMG/AMP guidelines and their mtDNA-specific specifications. Results: Ninety unique variants were identified (86.7% nuclear). A definitive molecular diagnosis was reached in 17% of patients, compared with 5.7% for mtDNA analysis alone: four primary mtDNA defects (MT-TS1, MT-CYB, MT-TL1, MT-ATP6), two nuclear-encoded mitochondrial disorders (ECHS1, FH) and six non-mitochondrial phenocopies (WFS1, ATP7B, G6PC1, ABCA4, KIF1A). A possible diagnosis was reached in 20% of patients, 46% were carriers of monoallelic variants in recessive genes, and 17% were negative. Conclusions: Simultaneous MITO-NUCLEAR NGS testing significantly increases diagnostic yield over single-genome screening. This single-step targeted panel offers a fast and efficient tool that facilitates variant identification across both genomes, supporting accurate clinical management and timely familial genetic counseling.